-

Ohio Becomes 21st State to Adopt Age-18 Sales Law for Cough Medicine

WASHINGTON--(BUSINESS WIRE)--To combat teen abuse of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM), Ohio Governor Mike DeWine today signed into law HB 9, prohibiting the sale of DXM-containing products to minors without a prescription. The law will take effect on September 29, 2021.

Ohio’s new law comes on the heels of the 2020 National Institute on Drug Abuse (NIDA) and University of Michigan’s annual survey, Monitoring the Future, which showed a slight increase in the percentage of teens who reported abusing OTC cough medicine over the last year – 3.7 percent in 2020 – up from 2.8 percent in 2019.

“The recent survey results, combined with stress of the ongoing pandemic, underscores the importance of remaining vigilant when it comes to preventing teen substance use,” said Scott Melville, President and CEO, Consumer Healthcare Products Association (CHPA). “In the case of OTC cough medicine, age-18 sales laws like the one signed by Governor DeWine are a proven way to prevent teen misuse, while maintaining nonprescription access for the millions of families who responsibly use products containing DXM to safely treat common cough symptoms.”

When used as directed, DXM is a safe and effective cough suppressant found in OTC cough and cold products. However, some teens report taking excessive amounts of DXM to get high, which can lead to harmful side effects.

“CHPA thanks Governor DeWine for signing this important bill into law, as well as Representative Koehler for his tireless leadership on this issue,” said Melville. “Smart public policy and education are both vitally important to combating teen OTC cough medicine abuse. This is why CHPA has long supported state efforts to limit teen access to DXM and has worked to increase parental awareness through its StopMedicineAbuse.org campaign.”

In 2012, California became the first state to prohibit sales of DXM-containing products to minors. Since then, governors from Alaska, Arizona, Delaware, Florida, Kentucky, Louisiana, New Jersey, New York, Tennessee, Virginia, Washington, Nevada, Oregon, Colorado, Wisconsin, Pennsylvania, West Virginia, Texas, and Michigan have all signed similar laws.

Recognizing the important role that retailers plan in the effective implementation of state DXM age-restriction laws, CHPA launched a retailer education initiative as part of its Stop Medicine Abuse campaign, aimed at engaging parents and community members about teen abuse of OTC cough medicine. Retailers can download or order free materials for employees and consumers.

Please visit StopMedicineAbuse.org for more information about teen DXM abuse and other helpful resources for parents and community members.

The Consumer Healthcare Products Association (CHPA), founded in 1881, is the national trade association representing the leading manufacturers and marketers of consumer healthcare products, including over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. CHPA is committed to empowering self-care by ensuring that Americans have access to products they can count on to be reliable, affordable, and convenient, while also delivering new and better ways to get and stay healthy. Visit www.chpa.org.

Contacts

Lauren Bloomberg, 202-429-3534, LBloomberg@chpa.org

Consumer Healthcare Products Association


Release Summary
OH DXM Bill
Release Versions

Contacts

Lauren Bloomberg, 202-429-3534, LBloomberg@chpa.org

Social Media Profiles
More News From Consumer Healthcare Products Association

Oregon Repeal of Unnecessary OTC Restrictions is a Dose of Good Policy for Consumers and Healthcare

WASHINGTON--(BUSINESS WIRE)--Now from coast-to-coast, it is once again legal to purchase cold and allergy medicines containing the decongestant pseudoephedrine (PSE) over-the-counter (OTC). In a major victory for consumers, Oregon has repealed a 15-year-old law that banned OTC sales of certain medicines for colds and allergies containing PSE. In 2006, Oregon became the first of two states to enact laws that made PSE a controlled substance only available with a doctor’s prescription (Rx). The ne...

CHPA Elects Johnson & Johnson’s Michelle Wang Goodridge as Board Chair

NEW HOPE, Pa.--(BUSINESS WIRE)--The Consumer Healthcare Products Association (CHPA) today announced the election of Michelle Wang Goodridge as the new Chair of the CHPA Board of Directors. Goodridge was elected on June 16th, along with six new board members, at CHPA’s annual membership meeting held during the association’s new Self-Care Leadership Summit. Goodridge, a standing member of CHPA’s Board of Directors since 2019, becomes the first female chair of the association. Currently, Goodridge...

CHPA Applauds Major Victory for Consumer Access to OTC Medicine in Mississippi

WASHINGTON--(BUSINESS WIRE)--In a major victory for consumer health, today Mississippi has repealed an 11-year-old law that banned over-the-counter (OTC) sales of certain medicines for colds and allergies containing the decongestant pseudoephedrine (PSE). Mississippi had previously allowed OTC PSE sales until 2010 when it categorized PSE as a Schedule III controlled substance making it only available with a doctor’s prescription (Rx). The new law returns PSE to OTC status allowing consumers to...
Back to Newsroom